Bristol Myers Squibb Co. (BMY)
61.15
-0.31
(-0.50%)
USD |
NYSE |
Oct 02, 16:00
61.14
-0.01
(-0.02%)
After-Hours: 20:00
Bristol Myers Squibb Enterprise Value : 158.92B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 158.92B |
| October 01, 2026 | 159.55B |
| September 30, 2026 | 161.47B |
| September 29, 2026 | 162.41B |
| September 28, 2026 | 164.49B |
| September 25, 2026 | 162.41B |
| September 24, 2026 | 159.63B |
| September 23, 2026 | 158.92B |
| September 22, 2026 | 161.16B |
| September 21, 2026 | 161.92B |
| September 18, 2026 | 162.82B |
| September 17, 2026 | 162.37B |
| September 16, 2026 | 163.92B |
| September 15, 2026 | 164.19B |
| September 14, 2026 | 164.94B |
| September 11, 2026 | 164.00B |
| September 10, 2026 | 164.23B |
| September 09, 2026 | 165.58B |
| September 08, 2026 | 166.15B |
| September 04, 2026 | 170.50B |
| September 03, 2026 | 173.09B |
| September 02, 2026 | 172.22B |
| September 01, 2026 | 170.70B |
| August 31, 2026 | 170.48B |
| August 28, 2026 | 170.01B |
| Date | Value |
|---|---|
| August 27, 2026 | 170.76B |
| August 26, 2026 | 172.03B |
| August 25, 2026 | 172.75B |
| August 24, 2026 | 171.44B |
| August 21, 2026 | 170.89B |
| August 20, 2026 | 167.74B |
| August 19, 2026 | 172.11B |
| August 18, 2026 | 168.93B |
| August 17, 2026 | 166.03B |
| August 14, 2026 | 164.39B |
| August 13, 2026 | 166.07B |
| August 12, 2026 | 164.13B |
| August 11, 2026 | 163.94B |
| August 10, 2026 | 166.45B |
| August 07, 2026 | 166.21B |
| August 06, 2026 | 165.04B |
| August 05, 2026 | 163.98B |
| August 04, 2026 | 168.60B |
| August 03, 2026 | 167.74B |
| July 31, 2026 | 167.41B |
| July 30, 2026 | 166.49B |
| July 29, 2026 | 162.90B |
| July 28, 2026 | 163.92B |
| July 27, 2026 | 161.80B |
| July 24, 2026 | 160.84B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 644.86B |
| Eli Lilly & Co. | 1.122T |
| Merck & Co., Inc. | 403.00B |
| Pfizer Inc. | 210.23B |
| AstraZeneca PLC | 512.95B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.316B |
| Revenue (Quarterly) | 12.98B |
| Total Expenses (Quarterly) | 9.665B |
| EPS Diluted (Quarterly) | 1.620 |
| Gross Profit Margin (Quarterly) | 67.95% |
| Profit Margin (Quarterly) | 25.54% |
| Earnings Yield | 7.42% |
| Operating Earnings Yield | 12.74% |
| Normalized Earnings Yield | 10.04 |